LUX-LUNG-3

NCT00949650 📎

Regimen

Experimental
afatinib
Control
cisplatin+pemetrexed

Population

Advanced EGFR-mut lung adenocarcinoma, chemo-naive

Key finding

mPFS 11.1 vs 6.9 mo, HR 0.58 (0.43-0.78); bigger benefit in del19/L858R common mutations

Source: PMID 23816960

Timeline

  • Enrollment start: 2009-08-14 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.112)